FDA and USP Develop New Approaches for Glycosylation Analysis
This article was originally published in The Gold Sheet
The growing number of biological products on the market is necessitating new approaches in the analysis and control of therapeutic glycoproteins. USP readies new chapters on glycosylation analysis and FDA describes high bar for approving manufacturing changes for protein therapeutic drugs.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.